ALT Stock — Altimmune, Inc.: Metrics

Market overview

2 metrics

Share price

$3.28

Market cap

$638.02M

Price action

19 metrics

Price change (1W)

-3.4%

Price change (30D)

+3.0%

Price change (3M)

+6.6%

Price change (6M)

-25.7%

Price change (YTD)

-14.4%

Price change (1Y)

-19.3%

Trailing year

Price change (5Y)

-79.9%

52-week high

$6.18

52-week low

$2.59

Change from 52-week high

-50.0%

Change from 52-week low

+19.3%

Annualized volatility

69.1%

Beta

1.5

RSI (14D)

52.5

Price vs SMA 50

+3.2%

Price vs SMA 200

-15.5%

Avg volume (3M)

4.36M

Relative volume

0.5

Average dollar volume

$12.83M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

194.52M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

14,754.9×

reciprocal yield 0.0%

P / book

1.3

reciprocal yield 78.4%

FCF yield

—

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-15.2%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-08-12

Profitability

9 metrics

Gross margin

—

Operating margin

-230,461.0%

Trailing 12 months

Net margin

-214,861.0%

Gross profit (TTM)

—

Operating profit (TTM)

−$100.22M

Net income (TTM)

−$91.76M

Trailing 12 months

Diluted EPS (TTM)

$-0.77

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$0.26

Growth

11 metrics

Revenue growth YoY

+420.0%

Year over year

Net income growth YoY

—

Revenue (TTM)

$41,000

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+127.6%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

-65.3%

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-19.4%

Return on assets

-17.4%

Debt / equity

—

Current ratio

26.8

EBITDA (TTM)

—

Free cash flow (TTM)

—

Quick ratio

26.8

Interest coverage

-28.3

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Cash & equivalents

$63.01M

Total assets

$527.21M

Total debt

$0

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$76.51M

Capital expenditures (TTM)

—

R&D (TTM)

$68.22M

SG&A (TTM)

—

Stock compensation (TTM)

$14.66M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

211

13F filer change QoQ

+37

Institutional ownership

78.8%

Short interest

3 metrics

Short interest

26.2%

Latest settlement · 11.0 days to cover

Days to cover

11.0d

Short-squeeze score

72 / 100

Insider activity

2 metrics

Net insider buying (90D)

$44,250

Insider-sentiment score

76 / 100

Risk flags

1 metrics

Going concern

—

ALT · Altimmune, Inc.

ALT metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search